APA (7th ed.) Citation

I, C. A., B, M. F., JL, S. G., N, L. A., A, S. G., V, F. C., . . . K, L. M. (2025). First-in-human evaluation of a no-alpha interleukin-2 mutein: Safety and preliminary pharmacodynamic and clinical effect. Frontiers in immunology, 16, 1589042. https://doi.org/10.3389/fimmu.2025.1589042

Chicago Style (17th ed.) Citation

I, Caballero Aguirrechu, et al. "First-in-human Evaluation of a No-alpha Interleukin-2 Mutein: Safety and Preliminary Pharmacodynamic and Clinical Effect." Frontiers in Immunology 16 (2025): 1589042. https://doi.org/10.3389/fimmu.2025.1589042.

MLA (9th ed.) Citation

I, Caballero Aguirrechu, et al. "First-in-human Evaluation of a No-alpha Interleukin-2 Mutein: Safety and Preliminary Pharmacodynamic and Clinical Effect." Frontiers in Immunology, vol. 16, 2025, p. 1589042, https://doi.org/10.3389/fimmu.2025.1589042.